Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease



Status:Recruiting
Conditions:Peripheral Vascular Disease, Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:Any - 17
Updated:4/6/2019
Start Date:May 15, 2018
End Date:December 31, 2020

Use our guide to learn which trials are right for you!

An Open-label, Randomised, Parallel-group, Multicentre, Observational Trial to Evaluate Safety and Efficacy of Edoxaban Tosylate in Children From 38 Weeks Gestational Age to Less Than 18 Years of Age With Cardiac Diseases at Risk of Thromboembolic Events

A committee will judge the safety and effectiveness of edoxaban and the regular treatment
(standard of care).

All children in the study will receive free treatment. They will have a 2 in 3 chance to
receive edoxaban, and a 1 in 3 chance to receive the standard of care for preventing blood
clots.

The study will find out if edoxaban is safer and more effective than the standard of care.

The primary objective is to compare the safety of edoxaban with the standard of care (SOC) in
pediatric subjects with cardiac diseases at risk of thromboembolic complications who need
primary or secondary anticoagulant prophylaxis with regard to the combination of major and
clinically relevant non-major (CRNM) bleeding per International Society on Thrombosis and
Haemostasis [ISTH] definition.

The key secondary objective is to compare the efficacy of edoxaban against SOC with regard to
the development of symptomatic thromboembolic events (TE) in the systemic arterial or venous
pathways including deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, intracardiac
thrombus and myocardial infarction (MI), and asymptomatic intracardiac thrombus identified by
cardiac imaging.

Inclusion Criteria:

- Is a child with cardiac disease who is at risk for thromboembolic complications and
requires at least 3 months antithrombotic anticoagulant prophylaxis

Either one of the following:

1. a child with cardiac disease who has a history of cardiac shunt occlusion/thrombosis,
with shunt still in place (secondary prevention).

OR

2. a child with cardiac disease who requires (including those already taking, and those
not yet taking) anticoagulation for primary prevention of TE.

Cardiac conditions known to significantly increase the risk of thrombosis (hence,
indications for primary TE prevention) are defined in Antithrombotic Therapy and Prevention
of Thrombosis. Some examples of cardiac conditions at risk of thrombosis are Fontan
surgery, heart failure, Kawasaki disease, and Blalock-Taussig and Glenn surgery.

- Is a male or female child between 1 and <18 years of age (children between 38 weeks
gestational age and 1 year of age will be included in the study, however, only after
the safety and efficacy data of 50 subjects between 1 and <18 years of age in the
edoxaban arm have been evaluated at the end of the 3-month treatment period)

- Has parent(s)/legal guardian(s) or legally acceptable representative who is informed
and provides signed consent for the child, to participate in the study with edoxaban
treatment. Pediatric participants with appropriate intellectual maturity will be
required to sign an assent form in addition to the signed informed consent from the
parent(s)/legal guardian(s) or any legally acceptable representative.

- If a female subject of childbearing potential, tests negative for pregnancy at
Screening and consents to avoid becoming pregnant by using a locally approved
contraception method throughout the study

Exclusion Criteria:

- Has evidence of symptomatic venous or arterial thrombosis and/or asymptomatic
intracardiac thrombosis confirmed by a transthoracic echocardiogram during study
screening period

- Has mechanical heart valve(s)

- Has active bleeding or high risk of bleeding contraindicating treatment with
anticoagulant

- Takes antithrombotic therapy (other than low-dose aspirin) that is not
protocol-related

- Administration of rifampin is prohibited during the study and subjects on concomitant
use of rifampin are excluded

- Has any hepatic disease associated with coagulopathy leading to a clinically relevant
bleeding risk

- Has estimated glomerular filtration rate (eGFR) <30% of normal for age and size

- Has stage 2 hypertension defined as blood pressure systolic and/or diastolic confirmed
>99th percentile plus 5 mmHg

- Has thrombocytopenia or life expectancy less than three months

- Has had Fontan procedure with a history of or signs/symptoms suggestive of
protein-losing enteropathy

- Is pregnant or breastfeeding

- Has a contraindication to the use of heparin and/or vitamin K antagonist (VKA)

- Has any condition that, as judged by the Investigator, would place the participant at
increased risk of harm if he/she participated in the study, including contraindicated
medications identified in the protocol
We found this trial at
10
sites
Seattle, Washington 98105
Phone: 206-987-5914
?
mi
from
Seattle, WA
Click here to add this to my saved trials
1720 2nd Ave S
Birmingham, Alabama 35233
(205) 934-4011 
Phone: 205-638-2018
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Charlotte, North Carolina 28204
Phone: 704-316-1220
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
1215 Lee St
Charlottesville, Virginia 22903
(434) 924-0211
Phone: 434-243-0910
University of Virginia Health System UVA Health System includes a 604-bed hospital, level I trauma...
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
115 Heart Drive
Greenville, North Carolina 27834
Phone: 252-744-2161
?
mi
from
Greenville, NC
Click here to add this to my saved trials
26–30 Krankenhausstraße
Linz, 4021
Phone: +43 576808424817
?
mi
from
Linz,
Click here to add this to my saved trials
Los Angeles, California 90048
Phone: 424-315-2297
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Mesa, Arizona 85202
Phone: 480-412-5561
?
mi
from
Mesa, AZ
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73104
Phone: 405-271-4411
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
1 Medical Center Blvd
Winston-Salem, North Carolina 27103
(336) 716-2011
Phone: 336-716-0308
Wake Forest University Baptist Medical Center Welcome to Wake Forest Baptist Medical Center, a fully...
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials